Cystic Fibrosis Ireland has set aside up to €120,000 ($141,150) to provide personal protective equipment (PPE) to people with cystic fibrosis (CF) in the Republic of Ireland. Those interested may apply for individual grants of €100 per applicant through Aug. 22. Applications to the PPE grant should be…
New research unveils why the bacteria Pseudomonas aeruginosa cause sustained infections in younger cystic fibrosis (CF) patients, while the bacteria Burkholderia cepacia complex infects patients as teenagers and adults. The findings show that P. aeruginosa loses the ability to use its toxic weaponry after it adapts to the lungs, allowing Burkholderia cepacia complex to…
The Cystic Fibrosis Foundation has committed $20 million to support the development of innovative therapeutics and early-stage companies focusing on cystic fibrosis (CF). In collaboration with venture capital firm Longwood Fund, the funding is part of the foundation’s Path to a Cure, a $500 million initiative…
A national newborn screening (NBS) program in the Republic of Ireland suggests that the incidence of cystic fibrosis and CF carriers in the country is lower than previously estimated, a study found. It also shows that the Gly551Asp mutation is almost three times more common among newborns in Ireland…
The Scottish Government and Vertex Pharmaceuticals have reached a deal to make Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor) available for people with cystic fibrosis (CF) once the medication receives its European license. This follows similar agreements in the three other U.K. countries, England, Wales, and Northern…
People with cystic fibrosis (CF) are more frequently infected with oral Candida fungus and carry a higher number of fungi than healthy individuals, a study has found. All fungal species identified in the study’s CF patients were susceptible to currently available anti-fungal medications. The study, “Oral…
The government of Northern Ireland reached a deal with Vertex Pharmaceuticals to make Kaftrio (ivacaftor/tezacaftor/elexacaftor) available for cystic fibrosis (CF) patients, once the medication receives its European license. The agreement follows similar ones that the company made recently with England and Wales.
A new study will assess the real-world effects of Vertex Pharmaceutical‘s Trikafta, a triple combo of elexacaftor, tezacaftor, and ivacaftor approved by the U.S. Food and Drug Administration (FDA) for treating up to 90% of all people with cystic fibrosis (CF). The $3.63 million study (3.06…
Researchers have developed the first thread-based flexible patch that can be sewn into clothing to monitor — in real time — several molecules in sweat, including chloride ions, which are dysregulated in cystic fibrosis (CF) patients. The study describing that finding, “Thread-based multiplexed sensor patch for…
This year’s Cystic Fibrosis Foundation (CFF) Impact Grants, which provide up to $10,000 in funding, will support and empower the cystic fibrosis (CF) community through four new virtual programs focused on engaging and connecting patients. Now in its fifth year, the program helps individuals and organizations whose projects…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.